Drug

Penbutolol

As of the edition of 20 October 2026, Penbutolol is a small molecule: marketed, first approved in 1987 (US); acts on ADRB1 and ADRB2; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1987
Kind
Small molecule
Brand name
Levatol
First approved
30 December 1987 (US)
Approvals on record
2 in 1 region
Holder of the most recent approval
Endo

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Companies that need a new molecule because of this drug

2 company-target rows on route B because of this drug.

Companies on route B for this drug

In the product

2 company-target rows are on route B because of Penbutolol.

Targets

GeneProteinUniProt
ADRB2Beta-2 adrenergic receptorP07550
ADRB1Beta-1 adrenergic receptorP08588

Who has held its approvals

CompanyRoleYears
UCBApplicant1989 to now
EndoAcquired holder2024 to now
Eli LillyOriginator1987 to 2024